Renovorx Inc Stock Price, News & Analysis

RenovoRx, a biopharmaceutical company, presented interim data from its Phase III TIGeR-PaC study at the AACR Annual Meeting. The analysis revealed that patients receiving the RenovoGem therapy for locally advanced pancreatic cancer exhibited a 60% improvement in median overall survival, reaching 16 months compared to 10 months for those on standard chemotherapy (IV gemcitabine and nab-paclitaxel). Additionally, RenovoGem patients experienced over a 65% reduction in adverse events such as nausea and fatigue. The Data Monitoring Committee found the results promising enough to continue the trial, which aims to enroll 114 patients. CEO Shaun Bagai emphasized the therapy's potential to change treatment protocols and enhance patient life quality. The next interim analysis is anticipated in mid to late 2024.

RenovoRx, a biopharmaceutical firm focused on localized cancer treatment, has appointed Leesa Gentry as the new Senior Vice President of Clinical Operations. Gentry, an expert with 29 years of experience in clinical trials management, is the fourth executive added to the management team recently. Her past roles include Senior Vice President at Evotec and significant contributions at PPD and Otsuka. The company is buoyed by positive interim data from its Phase III clinical trial on pancreatic cancer treatment, RenovoGem^TM. CEO Shaun Bagai expressed confidence in Gentry's ability to advance the company's clinical trials, enhancing its mission to improve patient outcomes in oncology.

RenovoRx, Inc. (Nasdaq: RNXT) announced a definitive agreement with an institutional investor to sell 1,557,632 shares of its common stock at $3.21 per share in a registered direct offering. The expected closing date is around April 3, 2023. Concurrently, the Company will issue warrants for an additional 1,947,040 shares at the same exercise price, with a term of five and a half years. Gross proceeds are anticipated to be approximately $5 million, aimed at working capital and general corporate purposes. Roth Capital Partners is the exclusive placement agent for this offering.

RenovoRx (NASDAQ: RNXT) announced promising interim data from its Phase III TIGeR-PaC trial for the RenovoGem therapy targeting pancreatic cancer. The results show a significant 6-month median overall survival benefit of 16 months for RenovoGem patients, compared to 10 months for those on standard IV chemotherapy. Notably, RenovoGem patients experienced over a 65% reduction in side effects like nausea and fatigue. These findings support discussions with the FDA to expedite further development. The second interim analysis is anticipated in mid-2024.

RenovoRx, Inc. (Nasdaq: RNXT) announced promising interim results from the Phase III TIGeR-PaC clinical trial for its product candidate, RenovoGem, aimed at treating locally advanced pancreatic cancer (LAPC).

The interim analysis indicates a 6-month increase in median overall survival in the RenovoGem group (16 months) compared to standard care (10 months). The trial is randomized, with 114 patients expected, and the current analysis included 45 patients. The Data Monitoring Committee recommends continuing the trial, with full data to be presented at the AACR Annual Meeting on April 17, 2023.

RenovoRx (Nasdaq: RNXT) reports financial results for 2022 and updates on its Phase III TIGeR-PaC clinical trial for localized pancreatic cancer treatment. The company has randomized 47 out of 114 patients, triggering its first interim analysis after recording 26 events (deaths). RenovoRx anticipates releasing the interim analysis results soon. Financially, cash and equivalents were $6.4 million at year-end, with total assets of $7.3 million against liabilities of $1.1 million. The company's net loss was $9.9 million, with a loss per share of ($1.09). Operating expenses increased to $10 million, driven by R&D and admin costs.

RenovoRx, a biopharmaceutical company focused on localized cancer treatment, announced CEO Shaun Bagai will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. Bagai will discuss the company's lead product candidate, RenovoGem™, which aims to disrupt standard chemotherapy with targeted intra-arterial delivery using the proprietary RenovoTAMP® platform. The pivotal Phase III TIGeR-PaC clinical trial for RenovoGem is ongoing, with the first interim analysis expected soon. RenovoRx also plans to investigate RenovoGem for extrahepatic cholangiocarcinoma in 2023.

RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company, announced that CEO Shaun Bagai will virtually present at the Sequire Biotechnology Conference on February 2, 2023, at 4 p.m. (ET). The presentation will focus on RenovoRx's innovative RenovoTAMP® therapy platform, which aims to transform cancer treatment by delivering localized chemotherapy directly to solid tumors, improving patients' quality of life. Bagai will also discuss the ongoing Phase III TIGeR-PaC clinical trial targeting locally advanced pancreatic cancer, with the first interim analysis expected soon. The event is open to the public for registration.

RenovoRx, Inc. (Nasdaq: RNXT) announced initial results from a pharmacokinetic substudy within the phase III TIGeR-PaC clinical trial at the 2023 ASCO GI Cancers Symposium. This trial evaluates the intra-arterial administration of gemcitabine for treating Locally Advanced Pancreatic Cancer (LAPC) using the RenovoTAMP platform. Preliminary findings indicate that the RenovoTAMP method may reduce systemic drug exposure by over 50%, potentially minimizing side effects while enhancing local chemotherapy delivery. Three additional supportive abstracts will also be presented, advancing the understanding of pancreatic cancer treatment.